BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 17062703)

  • 21. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.
    Kozlow W; Guise TA
    J Mammary Gland Biol Neoplasia; 2005 Apr; 10(2):169-80. PubMed ID: 16025223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biology of bone metastases: causes and consequences.
    Harvey HA; Cream Lv
    Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S7-S13. PubMed ID: 17683652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition.
    McCabe NP; Madajka M; Vasanji A; Byzova TV
    Clin Exp Metastasis; 2008; 25(5):581-90. PubMed ID: 18506587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.
    Nakajima K; Kho DH; Yanagawa T; Harazono Y; Hogan V; Chen W; Ali-Fehmi R; Mehra R; Raz A
    Cancer Res; 2016 Mar; 76(6):1391-402. PubMed ID: 26837763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloma and bone disease: "the dangerous tango".
    Epstein J; Walker R
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis.
    Das S; Samant RS; Shevde LA
    J Biol Chem; 2011 Mar; 286(11):9612-22. PubMed ID: 21169638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro.
    Krawetz R; Wu YE; Rancourt DE; Matyas J
    Exp Cell Res; 2009 Aug; 315(14):2333-42. PubMed ID: 19433087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombospondins in bone remodeling and metastatic bone disease.
    Carminati L; Taraboletti G
    Am J Physiol Cell Physiol; 2020 Dec; 319(6):C980-C990. PubMed ID: 32936697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
    Giuliani N; Rizzoli V; Roodman GD
    Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
    Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of cellular mechanisms of tumor osteolysis.
    Clohisy DR; Perkins SL; Ramnaraine ML
    Clin Orthop Relat Res; 2000 Apr; (373):104-14. PubMed ID: 10810467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.
    Schwaninger R; Rentsch CA; Wetterwald A; van der Horst G; van Bezooijen RL; van der Pluijm G; Löwik CW; Ackermann K; Pyerin W; Hamdy FC; Thalmann GN; Cecchini MG
    Am J Pathol; 2007 Jan; 170(1):160-75. PubMed ID: 17200191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteolytic and osteoblastic metastases due to carcinoid tumors.
    Manoli RS; Barthelemy CR
    Clin Nucl Med; 1980 Mar; 5(3):102-5. PubMed ID: 7357764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pathophysiology of bone metastases in urologic carcinomas].
    Sauer G; Barth TF; Möller P
    Urologe A; 2007 Aug; 46(8):888-90. PubMed ID: 17632696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.
    Min Y; Ren X; Vaught DB; Chen J; Donnelly E; Lynch CC; Lin PC
    Cancer Res; 2010 Apr; 70(7):2819-28. PubMed ID: 20233869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
    Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
    Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
    Reddi AH; Roodman D; Freeman C; Mohla S
    J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.